DURHAM, and NEW YORK, N.Y. — Duke University and Deerfield Management Company, a healthcare investment firm, have created a major translational research collaboration with $130 million in funding.
By way of a newly launched company called Four Points Innovation, up to $130 million of initial funding will be made available by Deerfield to back the initiative for 10 years.
Deerfield also will provide development expertise in support of Duke’s innovative drug research across a span of high-need therapeutic areas, as well as those targeting patients who suffer from hard-to-treat and rare diseases. .
Spearheaded by Duke University’s Office of Licensing & Ventures (OLV), the alliance is expected to accelerate Duke’s preclinical development of new drugs for improved quality of life and cures for disease.
“This is an exciting day for Duke and the patients we serve,” said Mary E. Klotman, MD, dean of the Duke University School of Medicine and vice chancellor for health affairs. “This new partnership will help further Duke’s commitment to improve the lives of people in our own community and around the world by supporting and accelerating the translation of research into new therapies to treat and cure society’s most formidable healthcare challenges.”
A private company wholly owned by affiliates of Deerfield, Four Points Innovation will support Duke R&D projects throughout preclinical stages of drug discovery and development. Beginning approximately in March 2020, Duke researchers will be able to submit project proposals for consideration by a Four Points Innovation committee comprised of scientific leadership representing both Duke and Deerfield.
Accepted projects will include a development plan aimed at achieving Investigational New Drug (IND) readiness. Deerfield will provide funding and operational support for accepted projects, and successful projects that achieve IND-enabled status may be eligible for additional capital from Deerfield.
Duke’s Office of Licensing and Ventures broke previous records last year with 354 invention disclosures, 120 agreements and 32 exclusive agreements. Duke faculty and staff formed 16 new start-up companies during the year, bringing the university’s total to more than 140 new companies. Over the last two years, 29 of the university’s 32 startups have chosen to stay in North Carolina.
“Duke University, with its vast research enterprise, world-class investigators and novel innovations, is a leader in biomedical discovery,” said James E. Flynn, managing partner at Deerfield Management. “We are excited about entering into this partnership with Duke, as we collectively seek to develop new medicines to save lives and address unmet medical needs.”
Under the terms of the agreement, Four Points Innovation would receive an option to license Four Points Innovation-funded intellectual property developed at Duke.